Galmed Pharmaceuticals Ltd
GLMD0.664USD
+0.069+11.58%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.64MMarket Cap
LossP/E TTM
More Details of Galmed Pharmaceuticals Ltd Company
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Galmed Pharmaceuticals Ltd Info
Ticker SymbolGLMD
Company nameGalmed Pharmaceuticals Ltd
IPO dateMar 13, 2014
CEOBaharaff (Allen)
Number of employees3
Security typeOrdinary Share
Fiscal year-endMar 13
Address16 Tiomkin Street
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6578317
Phone97236938448
Websitehttps://www.galmedpharma.com
Ticker SymbolGLMD
IPO dateMar 13, 2014
CEOBaharaff (Allen)
Company Executives of Galmed Pharmaceuticals Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+8834.00%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+6251.00%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+6251.00%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+6233.00%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+3123.00%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+3082.00%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
+3124.00%
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+8834.00%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+6251.00%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+6251.00%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+6233.00%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+3123.00%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+3082.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Jan 29
Updated: Thu, Jan 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
Other
98.30%
Shareholders
Shareholders
Proportion
Citadel Advisors LLC
0.71%
Baharaff (Allen)
0.52%
Two Sigma Investments, LP
0.30%
Nehemya (Guy)
0.09%
Stenzler (Yohai)
0.09%
Other
98.30%
Shareholder Types
Shareholders
Proportion
Hedge Fund
1.00%
Individual Investor
0.92%
Investment Advisor
0.05%
Other
98.03%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
29
75.39K
1.06%
-34.77K
2025Q3
29
75.58K
1.38%
-16.12K
2025Q2
36
135.24K
2.48%
+20.85K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citadel Advisors LLC
50.49K
0.71%
+50.49K
--
Sep 30, 2025
Baharaff (Allen)
36.94K
0.52%
+8.83K
+31.44%
Mar 21, 2025
Two Sigma Investments, LP
21.20K
0.3%
+21.20K
--
Sep 30, 2025
Nehemya (Guy)
6.28K
0.09%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.09%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.09%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.05%
+3.12K
+1148.16%
Mar 21, 2025
Sidransky (David)
3.12K
0.04%
+3.08K
+7338.10%
Mar 21, 2025
Poshinski (Amir)
3.12K
0.04%
+3.12K
--
Mar 21, 2025
UBS Financial Services, Inc.
963.00
0.01%
-5.94K
-86.05%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
Aug 28, 2024
Merger
12→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
May 12, 2023
Merger
15→1
